Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | ACE | P12821 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | MVD | P53602 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19658285 | 0.83 | ACE (0.37) | ACELMNARAB9ASMN1; SMN2PKM | |
| SCHEMBL19658286 | 0.83 | ACE (0.37) | ACELMNARAB9ASMN1; SMN2PKM | |
| SCHEMBL30439285 | 0.81 | PARP1 (0.39) | ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL9477001 | 0.81 | ACE (0.40) | ACELMNARAB9ASMN1; SMN2PKM | |
| SCHEMBL21100022 | 0.80 | CNR2 (0.35) | ACE | |
| SCHEMBL19658364 | 0.80 | ACE (0.35) | ACELMNARAB9ASMN1; SMN2PKM | |
| SCHEMBL9477009 | 0.78 | F2 (0.51) | ALDH1A1ACESMN1; SMN2 | |
| SCHEMBL7294804 | 0.77 | PREP (0.61) | — | |
| SCHEMBL18532509 | 0.77 | PARP1 (0.43) | — | |
| SCHEMBL29973394 | 0.76 | ALDH1A1 (0.44) | ALDH1A1ACELMNASMN1; SMN2NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210188895-A1 | SINGLE-STRANDED NUCLEIC ACID MOLECULE, AND PRODUCTION METHOD THEREFOR | BONAC CORPORATION (JP) | 2021-06-24 | — | — | US | disclosed |
| US-20210188895-A1 | SINGLE-STRANDED NUCLEIC ACID MOLECULE, AND PRODUCTION METHOD THEREFOR | BONAC CORPORATION (JP) | 2021-06-24 | — | — | US | disclosed |
| EP-3696269-A1 | SINGLE-STRANDED NUCLEIC ACID MOLECULE, AND PRODUCTION METHOD THEREFOR | Bonac Corporation (JP) | 2020-08-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210188895-A1 | SINGLE-STRANDED NUCLEIC ACID MOLECULE, AND PRODUCTION METHOD THEREFOR | POLRMT, POLL, RNGTT | ALDH1A1 1171/4885ACE 2561/4885LMNA 602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.